Sirtex

Alpha Holdings Urges OncoSec Stockholders to Vote Against China Grand Takeover Proposal at Special Meeting of Stockholders

Retrieved on: 
Friday, December 6, 2019
Professional services, Health, Finance, Clinical trials, Banking, Biotechnology, Radiation therapy, Sirtex, Proxy, Pharmaceutical industry in China, Health

Alpha urges OncoSec stockholders to vote AGAINST the transaction by returning the BLUE proxy card before the Special Meeting of Stockholders, currently scheduled for January 17, 2019.

Key Points: 
  • Alpha urges OncoSec stockholders to vote AGAINST the transaction by returning the BLUE proxy card before the Special Meeting of Stockholders, currently scheduled for January 17, 2019.
  • Alpha Holdings (Alpha or we) owns approximately 15.1% of the stock of OncoSec Medical Incorporated (OncoSec or the Company), which makes Alpha OncoSecs largest stockholder.
  • We are writing because we strongly oppose the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings (CGP) and Sirtex Medical US Holdings, Inc. (Sirtex), an affiliate of GCP (together, China Grand).
  • OncoSec claims that Torreya Partners concluded that the China Grand Takeover was the best option available to OncoSec.

OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

Retrieved on: 
Wednesday, December 4, 2019
General Health, Health, Oncology, Television series, American television series, Proxy, Articles, Company, Alphas, Board of directors, CGP, Sirtex, OncoSec Medical Incorporated

OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme buried in Alpha Holdings, Inc.s (Alpha) revised preliminary proxy statement filed on December 3, 2019.

Key Points: 
  • OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme buried in Alpha Holdings, Inc.s (Alpha) revised preliminary proxy statement filed on December 3, 2019.
  • OncoSec issued the following statement commenting on Alphas filing:
    We believe that Alpha is trying to game the system to engineer their preferred outcome.
  • We believe this is highly irregular and demonstrates Alphas troubling disregard for the votes and best interests of other OncoSec shareholders.
  • The bottom line is that Alpha has admitted that it may not vote the shares of shareholders who provide their proxies to Alpha.

OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements

Retrieved on: 
Monday, December 2, 2019
Biotechnology, General Health, Health, Clinical trials, Oncology, Economy, Finance, Money, Alpha, Investment, Mathematical finance, CGP, Sirtex, OncoSec Medical Incorporated

Below, we set the record straight by comparing the statements presented as facts by Alpha to reality.

Key Points: 
  • Below, we set the record straight by comparing the statements presented as facts by Alpha to reality.
  • Hee Do Koo, CEO of Alpha (Alpha Press Release, November 15, 2019)
    Reality: Mr. Koos math simply does not add up.
  • Bottom Line: Alphas misleading statements provide you with false information that could misguide you into making a decision that is harmful to your investment in OncoSec.
  • Bottom Line: Contrary to the false and misleading characterizations by Alpha, the Company ran a comprehensive process evaluating all strategic alternatives available to OncoSec.

Alpha Holdings Provides Update on Opposition to OncoSec Takeover Proposal

Retrieved on: 
Friday, November 15, 2019
Legal, Biotechnology, Finance, Health, Professional services, Technology, Semiconductor, Clinical trials, Radiation therapy, Sirtex

Alpha Holdings, Inc. (KOSDAQ: 117670) (Alpha Holdings), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (OncoSec or the Company), with an approximate 15.1% ownership stake, today provided an update with respect to its opposition of the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings (CGP) and Sirtex Medical US Holdings, Inc. (Sirtex), an affiliate of GCP (together, China Grand).

Key Points: 
  • Alpha Holdings, Inc. (KOSDAQ: 117670) (Alpha Holdings), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (OncoSec or the Company), with an approximate 15.1% ownership stake, today provided an update with respect to its opposition of the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings (CGP) and Sirtex Medical US Holdings, Inc. (Sirtex), an affiliate of GCP (together, China Grand).
  • On October 29, 2019, Alpha Holdings filed two lawsuits against OncoSec in the District Court of Clark County, Nevada.
  • The second lawsuit seeks access to certain OncoSec books and records, including the stockholder list that Alpha Holdings is legally entitled to use in connection with its effort to solicit votes in opposition to the China Grand Takeover Proposal.
  • A hearing on Alpha Holdings motion for a preliminary injunction blocking a stockholder vote on the China Grand Takeover Proposal is scheduled for January 13, 2020.

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer

Retrieved on: 
Wednesday, October 16, 2019
Radiation therapy, Sirtex

WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical , a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.

Key Points: 
  • WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical , a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.
  • The Sirtex Board unanimously appointed Smith based on his proven leadership, expertise in the healthcare and pharmaceutical space, and accomplishments during his tenure at Sirtex.
  • "Kevin is a remarkable member of the Sirtex senior leadership team who truly embodies our values and appreciates everyone in the Sirtex family," says Cathleen Lowndes, Chief Human Resources Officer of Sirtex.
  • "I am honored and excited to lead the outstanding team we have at Sirtex as Chief Executive Officer," says Kevin.

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer

Retrieved on: 
Wednesday, October 16, 2019
Radiation therapy, Sirtex

WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical , a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.

Key Points: 
  • WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical , a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.
  • The Sirtex Board unanimously appointed Smith based on his proven leadership, expertise in the healthcare and pharmaceutical space, and accomplishments during his tenure at Sirtex.
  • "Kevin is a remarkable member of the Sirtex senior leadership team who truly embodies our values and appreciates everyone in the Sirtex family," says Cathleen Lowndes, Chief Human Resources Officer of Sirtex.
  • "I am honored and excited to lead the outstanding team we have at Sirtex as Chief Executive Officer," says Kevin.

OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries

Retrieved on: 
Thursday, October 10, 2019
Radiation therapy, Sirtex, Royalty payment, U.S. Securities and Exchange Commission, Companies, Business law

Grand Decade will pay up to 20% royalties on the net sales of such products in the Territory.

Key Points: 
  • Grand Decade will pay up to 20% royalties on the net sales of such products in the Territory.
  • Sirtex will support and assist OncoSec with pre-marketing activities for TAVO and VLA in exchange for low single-digit royalties on TAVO and VLA net sales outside the Territory.
  • More details of the transaction documents can be found in OncoSec's filings with the U.S. Securities and Exchange Commission.
  • OncoSec anticipates filing for accelerated approval in the U.S. following the completion of its KEYNOTE-695 trial in 2020.

Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO

Retrieved on: 
Tuesday, October 1, 2019
RTT, Cancer, Clinical medicine, Infectious causes of cancer, Medicine, Colorectal cancer, NCI-designated Cancer Center, Cancer treatments, Angiogenesis inhibitors, Sirtex

"As of September 1, 2019, four patients have been treated and one has successfully completed their first cycle of treatment.

Key Points: 
  • "As of September 1, 2019, four patients have been treated and one has successfully completed their first cycle of treatment.
  • Colorectal cancer (CRC) is the second leading cause of cancer mortality in the U.S.
  • Despite significant progress in the treatment of mCRC, the majority of patients with metastatic disease succumb to the disease.
  • The trial is being conducted at two prestigious cancer centers: USC Norris Comprehensive Cancer Center and The Mayo Clinic Arizona.

Global Microspheres Industry

Retrieved on: 
Monday, August 26, 2019
Companies, AkzoNobel, Glass microsphere, Chemistry, Articles, Radiation therapy, Sirtex

US Microspheres Market Share (in %) by Company: 2019 & 2025

Key Points: 
  • US Microspheres Market Share (in %) by Company: 2019 & 2025
    Solid (Type) Competitor Revenue Share (in %) in the US: 2019 &
    Projections in US$ Million by Type: 2018 to 2025
    Table 35: Microspheres Market in the United States by Type: A
    Analysis in US$ Million by Application: 2018 to 2025
    in US$ Million by Type: 2018 to 2025
    Breakdown of Sales by Type for 2009, 2019, and 2025
    Microspheres in US$ Million by Application: 2018 to 2025
    Table 48: Japanese Microspheres Market Share Analysis by Type:
    Table 54: Chinese Microspheres Market by Type: Percentage
    Breakdown of Sales for 2009, 2019, and 2025
    Hollow (Type) Market Share (in %) by Company in Europe: 2019 &
    Solid (Type) Market Share (in %) of Major Players in Europe:
    in US$ Million by Application: 2018-2025
    in US$ Million by Type: 2018-2025
    Table 62: Microspheres Market in Europe in US$ Million by Type:
    Table 63: European Microspheres Market Share Breakdown by Type:
    in US$ Million by Application: 2018-2025
    Table 66: French Microspheres Market Share Analysis: A 17-Year
    Perspective by Application for 2009, 2019, and 2025
    Table 67: Microspheres Market in France by Type: Estimates and
    Table 69: French Microspheres Market Share Analysis by Type:
    Table 75: German Microspheres Market Share Breakdown by Type:
    Table 81: Italian Microspheres Market by Type: Percentage
    Breakdown of Sales for 2009, 2019, and 2025
    Microspheres in US$ Million by Application: 2018 to 2025
    Table 85: United Kingdom Market for Microspheres: Annual Sales
    Table 86: Microspheres Market in the United Kingdom: Historic
    Analysis in US$ Million by Application: 2018 to 2025
    in US$ Million by Type: 2018 to 2025
    Breakdown of Sales by Type for 2009, 2019, and 2025
    in US$ Million by Type: 2018 to 2025
    Table 98: Microspheres Market in Russia by Type: A Historic
    Table 99: Russian Microspheres Market Share Breakdown by Type:
    Opportunity in US$ Million by Application: 2018-2025
    Table 101: Microspheres Market in Rest of Europe: Summarization
    Forecasts in US$ Million by Type: 2018-2025
    Forecasts in US$ Million by Region/Country: 2018-2025
    Asia-Pacific in US$ Million by Application: 2018-2025
    Table 111: Asia-Pacific Microspheres Market Share Analysis: A
    17-Year Perspective by Application for 2009, 2019, and 2025
    Table 112: Microspheres Market in Asia-Pacific by Type:
    in US$ Million by Type: 2009-2017
    Analysis in US$ Million by Application: 2018 to 2025
    in US$ Million by Type: 2018 to 2025
    Breakdown of Sales by Type for 2009, 2019, and 2025
    Table 127: Microspheres Market in South Korea: Recent Past,
    in US$ Million by Application: 2009-2017
    Table 130: Microspheres Market in South Korea: Recent Past,
    in US$ Million by Type: 2009-2017
    for Microspheres in US$ Million by Application: 2018 to 2025
    Table 136: Rest of Asia-Pacific Market for Microspheres: Annual
    Table 137: Microspheres Market in Rest of Asia-Pacific:
    Breakdown of Sales by Region/Country: 2009, 2019, and 2025
    America in US$ Million by Type: 2009-2017
    Table 147: Latin American Microspheres Market by Type:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    Opportunity in US$ Million by Application: 2018-2025
    Forecasts in US$ Million by Type: 2018-2025
    in US$ Million by Application: 2018-2025
    Table 156: Brazilian Microspheres Market Share Analysis: A
    17-Year Perspective by Application for 2009, 2019, and 2025
    Table 157: Microspheres Market in Brazil by Type: Estimates and
    Table 165: Mexican Microspheres Market Share Breakdown by Type:
    Forecasts in US$ Million by Application: 2018 to 2025
    and Projections in US$ Million by Type: 2018 to 2025
    Forecasts in US$ Million by Region/Country: 2018-2025
    Demand Analysis in US$ Million by Application: 2018 to 2025
    Table 176: Microspheres Market in the Middle East:
    Forecasts in US$ Million by Type: 2018 to 2025
    Table 180: Microspheres Market in the Middle East: Percentage
    Share Breakdown of Sales by Type for 2009, 2019, and 2025
    Microspheres in US$ Million by Application: 2018 to 2025
    Table 186: Iranian Microspheres Market Share Analysis by Type:
    in US$ Million by Application: 2018-2025
    in US$ Million by Type: 2018-2025
    Table 192: Israeli Microspheres Market Share Breakdown by Type:
    Arabia in US$ Million by Type: 2009-2017
    Table 198: Saudi Arabian Microspheres Market by Type:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    Table 199: Microspheres Market in the United Arab Emirates:
    Analysis in US$ Million by Application: 2009-2017
    Table 202: Microspheres Market in the United Arab Emirates:
    Analysis in US$ Million by Type: 2009-2017
    Table 205: Microspheres Market in Rest of Middle East: Annual
    Retrospect in US$ Million by Application: 2009-2017
    Table 208: Microspheres Market in Rest of Middle East: Recent
    Analysis in US$ Million by Type: 2009-2017
    Projections in US$ Million by Type: 2018 to 2025
    Table 215: Microspheres Market in Africa by Type: A Historic
    Table 216: African Microspheres Market Share Breakdown by Type:
    IV.
  • COMPETITION3M COMPANYADVANCED POLYMERS INTERNATIONALAKZO NOBEL NVASIA PACIFIC MICROSPHERESBANGS LABORATORIES, INC.CENO TECHNOLOGIESCHASE CORPORATIONCOSPHERIC LLCDENNERT PORAVER GMBHDURGESH MERCHANDISE PVT.LUMINEX CORPORATIONMO-SCI CORPORATIONMATSUMOTO YUSHI-SEIYAKUMOMENTIVE PERFORMANCE MATERIALSNANJING JIANZUN GLASS MICROSPHERE PLANT CO., LTD.OMYA AG (OMYA GROUP)PETRA INDIA GROUP (PETRA INDIA PRODUCTS)POLYSCIENCESPOTTERS INDUSTRIES LLC.QINGDAO EASTCHEM INC.RESLAB MICROFILLERSIGMUND LINDNER GMBHSPHEROTECHTHE KISH COMPANY, INC.TRELLEBORG AB
    About Reportlinker ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients With Metastatic Disease [1]

Retrieved on: 
Tuesday, February 5, 2019
Medicine, Health, Radiation therapy, Cancer, Interventional oncology, Oncology, Radiology, Hepatology, Sirtex, SIR-Spheres

"Another option in that toolbox,TACE with Drug-Eluting Beads (DEBIRI with DC Bead), is already funded in the UK."

Key Points: 
  • "Another option in that toolbox,TACE with Drug-Eluting Beads (DEBIRI with DC Bead), is already funded in the UK."
  • The microspheres are delivered directly to liver tumours through the hepatic artery via catheter and become permanently lodged there.
  • BTG Interventional Oncology is committed to transforming the way cancer is treated with our portfolio of minimally-invasive, highly targeted cancer therapies that can be personalised to each patient's needs.
  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.